Multiomics – Products

Understanding the mechanisms of human disease requires a multiomic approach; however, legacy multiomic methods require multiple platforms and complex processes with lengthy turnaround times and considerable costs.

Revolutionary genomic research applied an innovative use of multiomics and biomimetic digital twins to unveil new DNA variants associated with the development of endometrial related disorders.

HiFi data generated on the Revioä system will support the EU and Estonian government-funded Center for Personalized Medicine and unlock discoveries across cardiology, mental and reproductive health, drug response, cancer research and rare diseases.

The PromethION 2 Integrated sets a new standard for convenience and efficiency in DNA, RNA, and cDNA sequencing. With its onboard computing capabilities, the self-contained device is bringing high-quality sequencing to a wider range of labs.

Companies have joined with industry leaders and FDA on Project PRISM to advance solutions that can improve the submission, review and ease of communication for human drug and biologics applications.

Azenta Life Sciences will officially open its new GENEWIZ Multiomics and Synthesis Solutions laboratory in Oxford, UK in March 2024.

New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins.

Study demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies. Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry.

Company announces roadmap anchored by new two plate workflow enabling preparation of samples up to 2 million cells and beyond. New collaborations with Vizgen, BioLegend, and SPT Labtech will extend range.

The project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial. The Assay will be available as a service in the Babraham Institute’s Flow Cytometry Facility.